A drug for treating diabetes similar to popular weight-loss medicines such as Ozempic did not show any benefits for people ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

China's Foreign Ministry spokesman Lin Jian said at a briefing that China 'firmly opposes the US smearing and undermining the ...